Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator.

Thomas R, Shinagare AB, Rosenthal MH, Lee B, Jacene HA, Johnston MA, Overmoyer BA.

Clin Imaging. 2019 Nov 20;59(2):100-103. doi: 10.1016/j.clinimag.2019.08.008. [Epub ahead of print] No abstract available.

PMID:
31812880
2.

Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).

Sharma MR, Mehrotra S, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Velasco M, Overmoyer B, Rugo HS, Ratain MJ, Gobburu JV.

J Clin Pharmacol. 2019 Dec 4. doi: 10.1002/jcph.1559. [Epub ahead of print]

PMID:
31802506
3.

Aggressive Subsets of Metastatic Triple Negative Breast Cancer.

Singh J, Asad S, Zhang Y, Nock W, Adams E, Damicis A, Ramaswamy B, Williams N, Parsons HA, Adalsteinsson VA, Winer EP, Lin NU, Partridge AH, Overmoyer B, Stover DG.

Clin Breast Cancer. 2019 Jul 31. pii: S1526-8209(19)30160-0. doi: 10.1016/j.clbc.2019.06.012. [Epub ahead of print]

PMID:
31631016
4.

Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana-Farber Cancer Institute's Inflammatory Breast Cancer Program experience.

Nakhlis F, Regan MM, Chun YS, Dominici LS, Caterson S, Bellon JR, Warren L, Yeh ED, Jacene HA, King TA, Overmoyer B.

Breast J. 2019 Aug 25. doi: 10.1111/tbj.13509. [Epub ahead of print]

PMID:
31448540
5.

Inflammatory Breast Cancer: a Separate Entity.

Rosenbluth JM, Overmoyer BA.

Curr Oncol Rep. 2019 Aug 15;21(10):86. doi: 10.1007/s11912-019-0842-y. Review.

PMID:
31414257
6.

Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.

Devi GR, Hough H, Barrett N, Cristofanilli M, Overmoyer B, Spector N, Ueno NT, Woodward W, Kirkpatrick J, Vincent B, Williams KP, Finley C, Duff B, Worthy V, McCall S, Hollister BA, Palmer G, Force J, Westbrook K, Fayanju O, Suneja G, Dent SF, Hwang ES, Patierno SR, Marcom PK.

J Cancer. 2019 Jun 4;10(15):3344-3351. doi: 10.7150/jca.31176. eCollection 2019. Review.

7.

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma.

Mayer EL, DeMichele A, Rugo HS, Miller K, Waks AG, Come SE, Mulvey T, Jeselsohn R, Overmoyer B, Guo H, Barry WT, Huang Bartlett C, Koehler M, Winer EP, Burstein HJ.

Ann Oncol. 2019 Sep 1;30(9):1514-1520. doi: 10.1093/annonc/mdz198.

PMID:
31250880
8.

Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).

Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM.

Breast Cancer Res Treat. 2019 Jul;176(2):303-310. doi: 10.1007/s10549-019-05238-4. Epub 2019 Apr 19.

PMID:
31004299
9.

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP.

J Clin Oncol. 2019 Aug 1;37(22):1868-1875. doi: 10.1200/JCO.19.00066. Epub 2019 Apr 2.

PMID:
30939096
10.

Prevalence of germline variants in inflammatory breast cancer.

Rana HQ, Sacca R, Drogan C, Gutierrez S, Schlosnagle E, Regan MM, Speare V, LaDuca H, Dolinsky J, Garber JE, Overmoyer BA.

Cancer. 2019 Apr 1. doi: 10.1002/cncr.32062. [Epub ahead of print]

PMID:
30933323
11.

Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.

Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B; Dana-Farber Cancer Institute Inflammatory Breast Cancer Program.

Clin Breast Cancer. 2019 Apr;19(2):146-155. doi: 10.1016/j.clbc.2018.11.010. Epub 2018 Nov 26.

PMID:
30584057
12.

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).

Rashkin SR, Chua KC, Ho C, Mulkey F, Jiang C, Mushiroda T, Kubo M, Friedman PN, Rugo HS, McLeod HL, Ratain MJ, Castillos F, Naughton M, Overmoyer B, Toppmeyer D, Witte JS, Owzar K, Kroetz DL.

Clin Pharmacol Ther. 2019 Mar;105(3):738-745. doi: 10.1002/cpt.1241. Epub 2018 Nov 1.

13.

Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer.

Stover DG, Gil Del Alcazar CR, Brock J, Guo H, Overmoyer B, Balko J, Xu Q, Bardia A, Tolaney SM, Gelman R, Lloyd M, Wang Y, Xu Y, Michor F, Wang V, Winer EP, Polyak K, Lin NU.

NPJ Breast Cancer. 2018 May 4;4:10. doi: 10.1038/s41523-018-0060-z. eCollection 2018.

14.

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA.

J Cancer. 2018 Apr 6;9(8):1437-1447. doi: 10.7150/jca.23969. eCollection 2018.

15.

Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.

Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT.

J Cancer. 2017 Oct 9;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017.

16.

Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

Jagsi R, Griffith KA, Bellon JR, Woodward WA, Horton JK, Ho A, Feng FY, Speers C, Overmoyer B, Sabel M, Schott AF, Pierce L; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2018 May 1;36(13):1317-1322. doi: 10.1200/JCO.2017.77.2665. Epub 2018 Mar 20.

17.

Pure Intralymphatic Invasion in the Absence of Stromal Invasion After Neoadjuvant Therapy: A Rare Pattern of Residual Breast Carcinoma.

Guilbert MC, Overmoyer B, Lester SC.

Am J Surg Pathol. 2018 May;42(5):679-686. doi: 10.1097/PAS.0000000000001029.

PMID:
29394169
18.

Vocal fold paralysis on positron emission tomography-CT.

Ma C, Frosch ZA, Overmoyer B, Cooper AZ.

Thorax. 2018 Jan;73(1):97-98. doi: 10.1136/thoraxjnl-2016-209261. Epub 2017 Jul 17. No abstract available.

PMID:
28717033
19.

Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).

Mehrotra S, Sharma MR, Gray E, Wu K, Barry WT, Hudis C, Winer EP, Lyss AP, Toppmeyer DL, Moreno-Aspitia A, Lad TE, Valasco M, Overmoyer B, Rugo H, Ratain MJ, Gobburu JV.

AAPS J. 2017 Sep;19(5):1411-1423. doi: 10.1208/s12248-017-0101-9. Epub 2017 Jun 15.

20.

The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.

Nakhlis F, Regan MM, Warren LE, Bellon JR, Hirshfield-Bartek J, Duggan MM, Dominici LS, Golshan M, Jacene HA, Yeh ED, Mullaney EE, Overmoyer B.

Ann Surg Oncol. 2017 Sep;24(9):2563-2569. doi: 10.1245/s10434-017-5903-6. Epub 2017 May 30.

PMID:
28560598
21.

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.

Tolaney SM, Ziehr DR, Guo H, Ng MR, Barry WT, Higgins MJ, Isakoff SJ, Brock JE, Ivanova EV, Paweletz CP, Demeo MK, Ramaiya NH, Overmoyer BA, Jain RK, Winer EP, Duda DG.

Oncologist. 2017 Jan;22(1):25-32. doi: 10.1634/theoncologist.2016-0229. Epub 2016 Oct 27.

22.

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance).

Golshan M, Cirrincione CT, Sikov WM, Carey LA, Berry DA, Overmoyer B, Henry NL, Somlo G, Port E, Burstein HJ, Hudis C, Winer E, Ollila DW; Alliance for Clinical Trials in Oncology.

Breast Cancer Res Treat. 2016 Nov;160(2):297-304. Epub 2016 Oct 4.

23.

Metastasis to the Cervix Uteri 15 Years After Treatment of Lobular Carcinoma of the Breast.

Waks AG, Lennon J, Yadav BS, Hwang H, dSchapirael Carmen M, Johnson NB, Reynolds K, Schapira L, Gilman PB, Overmoyer B.

Semin Oncol. 2015 Aug;42(4):e81-94. doi: 10.1053/j.seminoncol.2015.07.002. Epub 2015 Jul 6. No abstract available.

PMID:
26320072
24.

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer.

Tolaney SM, Tan S, Guo H, Barry W, Van Allen E, Wagle N, Brock J, Larrabee K, Paweletz C, Ivanova E, Janne P, Overmoyer B, Wright JJ, Shapiro GI, Winer EP, Krop IE.

Invest New Drugs. 2015 Oct;33(5):1108-14. doi: 10.1007/s10637-015-0269-8. Epub 2015 Jul 1.

25.

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM.

Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16.

26.

Inflammatory breast cancer and development of brain metastases: risk factors and outcomes.

Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR.

Breast Cancer Res Treat. 2015 May;151(1):225-32. doi: 10.1007/s10549-015-3381-8. Epub 2015 Apr 17.

PMID:
25893587
27.

Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.

Warren LE, Guo H, Regan MM, Nakhlis F, Yeh ED, Jacene HA, Hirshfield-Bartek J, Overmoyer BA, Bellon JR.

Ann Surg Oncol. 2015 Aug;22(8):2483-91. doi: 10.1245/s10434-015-4469-4. Epub 2015 Mar 20.

PMID:
25791789
28.

Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever?

Overmoyer B.

J Clin Oncol. 2015 Mar 10;33(8):823-8. doi: 10.1200/JCO.2014.58.2361. Epub 2015 Jan 26. No abstract available.

PMID:
25624431
29.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP.

N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281. Erratum in: N Engl J Med. 2015 Nov 12;373(20):1989.

30.

Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets.

Nienhuis HH, Gaykema SB, Timmer-Bosscha H, Jalving M, Brouwers AH, Lub-de Hooge MN, van der Vegt B, Overmoyer B, de Vries EG, Schröder CP.

Pharmacol Ther. 2015 Mar;147:63-79. doi: 10.1016/j.pharmthera.2014.11.004. Epub 2014 Nov 6. Review.

PMID:
25444756
31.

What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach.

Yeh ED, Jacene HA, Bellon JR, Nakhlis F, Birdwell RL, Georgian-Smith D, Giess CS, Hirshfield-Bartek J, Overmoyer B, Van den Abbeele AD.

Radiographics. 2013 Nov-Dec;33(7):2003-17. doi: 10.1148/rg.337135503.

PMID:
24224593
32.

Prospective clinical experience with research biopsies in breast cancer patients.

Vaz-Luis I, Zeghibe CA, Frank ES, Sohl J, Washington KE, Silverman SG, Fonte JM, Mayer EL, Overmoyer BA, Richardson AL, Krop IE, Winer EP, Lin NU.

Breast Cancer Res Treat. 2013 Nov;142(1):203-9. doi: 10.1007/s10549-013-2717-5. Epub 2013 Oct 11.

33.

Microinvasive breast cancer: ER, PR, and HER-2/neu status and clinical outcomes after breast-conserving therapy or mastectomy.

Margalit DN, Sreedhara M, Chen YH, Catalano PJ, Nguyen PL, Golshan M, Overmoyer BA, Harris JR, Brock JE.

Ann Surg Oncol. 2013 Mar;20(3):811-8. doi: 10.1245/s10434-012-2640-8. Epub 2012 Sep 7.

PMID:
22956068
34.

Case records of the Massachusetts General Hospital. Case 17-2011. A 49-year-old woman with a mass in the breast and overlying skin changes.

Overmoyer BA, Lee JM, Lerwill MF.

N Engl J Med. 2011 Jun 9;364(23):2246-54. doi: 10.1056/NEJMcpc1100922. No abstract available.

PMID:
21651397
35.

A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer.

Chen WC, Kim J, Kim E, Silverman P, Overmoyer B, Cooper BW, Anthony S, Shenk R, Leeming R, Hanks SH, Lyons JA.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):14-20. doi: 10.1016/j.ijrobp.2010.08.051. Epub 2010 Oct 29.

PMID:
21035961
36.

Inflammatory breast cancer: novel preoperative therapies.

Overmoyer BA.

Clin Breast Cancer. 2010 Feb;10(1):27-32. doi: 10.3816/CBC.2010.n.003. Review.

PMID:
20133255
37.

A vasculature-targeting regimen of preoperative docetaxel with or without bevacizumab for locally advanced breast cancer: impact on angiogenic biomarkers.

Baar J, Silverman P, Lyons J, Fu P, Abdul-Karim F, Ziats N, Wasman J, Hartman P, Jesberger J, Dumadag L, Hohler E, Leeming R, Shenk R, Chen H, McCrae K, Dowlati A, Remick SC, Overmoyer B.

Clin Cancer Res. 2009 May 15;15(10):3583-90. doi: 10.1158/1078-0432.CCR-08-2917. Epub 2009 May 5.

38.

Options for the treatment of patients with taxane-refractory metastatic breast cancer.

Overmoyer B.

Clin Breast Cancer. 2008 Mar;8 Suppl 2:S61-70. Review.

PMID:
18637401
39.

Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.

Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA 3rd.

J Clin Oncol. 2008 Jul 10;26(20):3317-23. doi: 10.1200/JCO.2007.13.5202. Epub 2008 May 19.

PMID:
18490651
40.

Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine.

Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC.

Cancer Chemother Pharmacol. 2009 Feb;63(3):441-50. doi: 10.1007/s00280-008-0754-2. Epub 2008 Apr 15.

41.

Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin.

Overmoyer B, Fu P, Hoppel C, Radivoyevitch T, Shenk R, Persons M, Silverman P, Robertson K, Ziats NP, Wasman JK, Abdul-Karim FW, Jesberger JA, Duerk J, Hartman P, Hanks S, Lewin J, Dowlati A, McCrae K, Ivy P, Remick SC.

Clin Cancer Res. 2007 Oct 1;13(19):5862-8.

42.

Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules.

Burstein HJ, Overmoyer B, Gelman R, Silverman P, Savoie J, Clarke K, Dumadag L, Younger J, Ivy P, Winer EP.

Invest New Drugs. 2007 Apr;25(2):161-4. Epub 2006 Sep 13.

PMID:
16969707
43.

Breast conservation surgery achieving>or=2 mm tumor-free margins results in decreased local-regional recurrence rates.

Kunos C, Latson L, Overmoyer B, Silverman P, Shenk R, Kinsella T, Lyons J.

Breast J. 2006 Jan-Feb;12(1):28-36.

PMID:
16409584
44.

Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer.

Cooper BW, Radivoyevitch T, Overmoyer BA, Shenk RR, Pham HT, Samuels JR, Parry MP, Silverman P.

Breast Cancer Res Treat. 2006 Jun;97(3):311-8. Epub 2005 Dec 13.

PMID:
16344915
45.

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM.

J Clin Oncol. 2005 Aug 20;23(24):5542-51.

PMID:
16110015
46.

Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer.

Overmoyer B, Silverman P, Holder LW, Tripathy D, Henderson IC.

Clin Breast Cancer. 2005 Jun;6(2):150-7.

PMID:
16001993
47.

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.

Burris HA 3rd, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL.

J Clin Oncol. 2005 Aug 10;23(23):5305-13. Epub 2005 Jun 13.

PMID:
15955900
48.

The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer.

Robert NJ, Vogel CL, Henderson IC, Sparano JA, Moore MR, Silverman P, Overmoyer BA, Shapiro CL, Park JW, Colbern GT, Winer EP, Gabizon AA.

Semin Oncol. 2004 Dec;31(6 Suppl 13):106-46. Review.

PMID:
15717740
49.

Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies.

Spector NL, Xia W, Burris H 3rd, Hurwitz H, Dees EC, Dowlati A, O'Neil B, Overmoyer B, Marcom PK, Blackwell KL, Smith DA, Koch KM, Stead A, Mangum S, Ellis MJ, Liu L, Man AK, Bremer TM, Harris J, Bacus S.

J Clin Oncol. 2005 Apr 10;23(11):2502-12. Epub 2005 Jan 31.

PMID:
15684311
50.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS.

J Clin Oncol. 2005 Feb 1;23(4):792-9.

PMID:
15681523

Supplemental Content

Loading ...
Support Center